Developer docs
API playgroundTry for free, no card

Search company profiles

Locate Bio

Full company profile

uuid00024ps

Namestring
Locate Bio
Legal namestring
Locate Bio Ltd
Websiteurl
locatebio.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Locate Bio is a UK-based clinical-stage orthobiologics company developing next-generation bone graft substitutes and regenerative medicine products for musculoskeletal applications. Its portfolio spans five product candidates — LDGraft (controlled-release rhBMP-2 for spinal fusion), CertOss (synthetic instructive tissue scaffold bone graft), OsteoMime (stealth rhBMP-2 product for revision spinal surgeries), CognitOss (antibiotic-releasing resorbable graft for osteomyelitis), and Chondro3 (three-layer biomimetic cartilage repair graft) — built on two proprietary platforms: Programmed Drug Release and Instructive Tissue Scaffolds. The lead technology, a polymer-encapsulation Dose Shielding system, is designed to deliver rhBMP-2 in a controlled, biomimetic profile over 4–6 weeks, with preclinical data showing fusion equivalence to iliac crest autograft in a sheep model at 6 months.

The company targets spine surgeons and orthopedic surgeons performing spinal fusion and related procedures in hospitals and surgical centers, addressing limitations of autograft (donor site morbidity), allograft (disease transmission risk), and existing rhBMP-2 products (supraphysiological dosing and inflammatory side effects). LDGraft received FDA Breakthrough Device designation in May 2023, and the RESTORE clinical study commenced US enrollment in November 2024. The company is a spin-out from the University of Nottingham (founded on the regenerative medicine research of Professor Kevin Shakesheff) and has raised over £27 million in cumulative funding from Mercia Ventures, BGF, MEIF, and Innovate UK.

Locate Bio currently generates no product revenue; its commercial model is built around future direct sales to healthcare institutions via clinical field sales representatives, with complementary out-licensing potential for its TAOS and IntraStem platforms. Revenue mechanics will activate post-regulatory approval, with the US market (over 700,000 spinal fusions annually) as the primary near-term opportunity, supported by a wholly-owned US subsidiary, Locate Bio Inc.

Short descriptiontext

Locate Bio is a UK clinical-stage orthobiologics company developing polymer-encapsulated rhBMP-2 bone graft substitutes and instructive tissue scaffolds for spine and orthopedic surgeons, with LDGraft in US clinical trials for spinal fusion.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNottingham, United Kingdom
HQ citystring
Nottingham
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
orthobiologics products, bone graft substitutes, spinal fusion devices, tissue engineering scaffolds, controlled drug release
Industry3 codes
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Surgical Appliance and Supplies Manufacturing339113
  • Medical Equipment and Supplies Manufacturing3391
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Biological Products, (No Disgnostic Substances)2836
Product category
Orthobiologics — Bone Graft Substitutes
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Product Sales (Post-Approval)
TypeOne Time License
Description

Revenue from sales of LDGraft, CertOss, and other orthobiologics products to hospitals and surgeons upon regulatory approval. Currently pre-revenue as products are in clinical development stage.

businesswire.com
2Licensing and Partnerships
TypeLicensing Royalties
Description

Potential out-licensing or partnering opportunities for proprietary technologies including TAOS platform and IntraStem gene therapy technology to pharmaceutical and medical device companies.

locatebio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1LDGraft
Description

rhBMP-2 bone graft substitute product for spinal fusion with FDA breakthrough device designation

locatebio.com
+4 more records
Core offering1 text field

Locate Bio develops and manufactures orthobiologics products — bone graft substitutes and tissue scaffolds — for use by spine and orthopedic surgeons in spinal fusion, bone infection, and cartilage repair procedures. Its portfolio combines Programmed Drug Release technology (sustained, biomimetic rhBMP-2 delivery) with Instructive Tissue Scaffold technology (100% synthetic calcium phosphate scaffolds), producing products such as LDGraft, CertOss, OsteoMime, CognitOss, and Chondro3.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • All three rhBMP-2 doses tested were equivalent to iliac crest bone graft in terms of fusion at 6 months in sheep model
+2 more records
Product overview1 text field

Locate Bio is a diversified orthobiologics company developing multiple product families using two core technology platforms: Programmed Drug Release and Instructive Tissue Scaffolds. The portfolio includes LDGraft (controlled-release rhBMP-2 for spinal fusion), CertOss (100% synthetic bone graft scaffold), OsteoMime (second-generation rhBMP-2 product for revision surgeries), CognitOss (antibiotic-delivering bone graft for osteomyelitis), and Chondro3 (biomimetic cartilage repair graft). The products address unmet musculoskeletal needs in spinal fusion, bone infection treatment, and cartilage repair.

Product and service5 records
1LDGraft™
CategoryBone graft substitute — spinal fusion
Description

A next-generation bone graft substitute for spinal fusion featuring 100% pre-encapsulated recombinant human bone morphogenetic protein-2 (rhBMP-2) with controlled and extended release over 4-6 weeks. Uses Dose Shielding technology to shield rhBMP-2 during the early inflammatory phase and enables a biomimetic release profile aligned with the 7-14 day natural peak of BMP-2 expression in human bone healing. Investigational use only; holds FDA Breakthrough Device designation for ALIF.

2CertOss™
CategorySynthetic bone graft substitute — orthopedic / spine
Description

A 100% synthetic bone graft substitute using Instructive Tissue Scaffold technology. Developed through R&D evaluating geometries to deliver novel bone graft properties based on discoveries that new bone forms preferentially on concave surfaces of ceramic grafts and that submicron surface topography differences result in enhanced bone mineralization.

3OsteoMime™
CategoryBone graft substitute — revision spinal surgery
Description

A second rhBMP-2 product in development using Programmed Drug Release technology, currently in stealth mode, designed to address unmet needs in revision spinal surgeries.

4CognitOss
CategoryAntibiotic-eluting bone graft — osteomyelitis treatment
Description

Controlled and responsive release of antibiotics from a resorbable bone graft for the treatment of osteomyelitis (bone infections). Combines local delivery of therapeutically appropriate levels of antibiotics from a smart material responsive to the presence of infection while promoting bone regeneration. Received FDA Breakthrough Device designation.

5Chondro3
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-09-03
Description

TAOS technology partnered with a major European orthopaedics company for osteomyelitis treatment application.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-09-01
Description

Locate Bio acquired multiple late-stage complementary orthobiologics assets from RCSI University of Medicine and Health Sciences, accelerating route to market and broadening orthobiologics pipeline with products including CertOss, CognitOss, and Chondro3.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2018-10-16
Description

Locate Bio is a spin-out from the University of Nottingham based on the research of Professor Kevin Shakesheff, a world-leading expert in regenerative medicine. The company was initially a contract research organization before pivoting to orthobiologics product development.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

SeaSpine (now part of Globus Medical) is a spine-focused orthobiologics company offering bone graft substitutes and spinal fusion products. Its portfolio overlaps directly with Locate Bio's spinal fusion and bone graft ambitions, and Keith Valentine served as its CEO, illustrating the direct comparability.

TypeBroad incumbent
Description

Baxter acquired ApaTech (where Locate Bio's CEO previously served) for $330M, validating the strategic value of differentiated orthobiologics assets. As a major medical device incumbent with a bone graft substitute franchise, Baxter represents both a competitor and a potential strategic acquirer profile.

TypeDirect peer
Description

Bioventus is an orthobiologics-focused company offering bone graft substitutes and regenerative medicine products for spine and orthopedic applications. Its portfolio overlaps with Locate Bio's CertOss and CognitOss franchises, making it a comparable pure-play orthobiologics peer.

TypeBroad incumbent
Description

NuVasive (now part of Globus Medical) is a major spine surgery company with a substantial orthobiologics portfolio. Its spinal fusion franchise and biologics offerings compete in the same surgeon call point as Locate Bio, and Keith Valentine previously served as President and COO.

TypeDirect peer
Description

Orthofix is a spine and orthopedics company with a meaningful orthobiologics segment including bone graft substitutes. Its BGM (Biologics) product line directly competes with Locate Bio's CertOss and LDGraft in the spinal fusion call point.

TypeDirect peer
Description

Xtant Medical is a clinical-stage and commercial orthobiologics company developing bone graft substitutes and regenerative products for spinal and orthopedic surgery. Its product portfolio and pipeline stage are highly comparable to Locate Bio's diversified orthobiologics approach.

TypeEmerging player
Description

Prosidyan (acquired by Globus Medical) developed synthetic bone graft substitutes with biologic activity for spine and orthopedic surgery. Its focus on synthetic, growth-factor-enhanced grafts is directly comparable to Locate Bio's CertOss and LDGraft strategy.

TypeBroad incumbent
Description

Medtronic markets INFUSE, the established rhBMP-2 bone graft substitute that LDGraft is designed to displace or compete against in spinal fusion. As the dominant incumbent in rhBMP-2 delivery with decades of clinical data and entrenched surgeon relationships, it is the most direct competitive benchmark for Locate Bio's lead program.

9Bone Biologics
TypeEmerging player
Description

Bone Biologics is a clinical-stage orthobiologics company developing bone graft substitutes for spinal fusion using rhBMP-2. It is a direct competitor to Locate Bio's LDGraft in the same indication, technology class, and clinical development stage.

TypeDirect peer
Description

MTF Biologics is a leading tissue bank and orthobiologics provider offering allograft bone graft substitutes for spinal fusion and orthopedic applications. Its allograft-based offerings compete directly with Locate Bio's synthetic CertOss and LDGraft products.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Locate Bio

Orthobiologics — Bone Graft Substituteslocatebio.com

Locate Bio is a UK clinical-stage orthobiologics company developing polymer-encapsulated rhBMP-2 bone graft substitutes and instructive tissue scaffolds for spine and orthopedic surgeons, with LDGraft in US clinical trials for spinal fusion.

What Locate Bio does

Locate Bio is a UK-based clinical-stage orthobiologics company developing next-generation bone graft substitutes and regenerative medicine products for musculoskeletal applications. Its portfolio spans five product candidates — LDGraft (controlled-release rhBMP-2 for spinal fusion), CertOss (synthetic instructive tissue scaffold bone graft), OsteoMime (stealth rhBMP-2 product for revision spinal surgeries), CognitOss (antibiotic-releasing resorbable graft for osteomyelitis), and Chondro3 (three-layer biomimetic cartilage repair graft) — built on two proprietary platforms: Programmed Drug Release and Instructive Tissue Scaffolds. The lead technology, a polymer-encapsulation Dose Shielding system, is designed to deliver rhBMP-2 in a controlled, biomimetic profile over 4–6 weeks, with preclinical data showing fusion equivalence to iliac crest autograft in a sheep model at 6 months.

The company targets spine surgeons and orthopedic surgeons performing spinal fusion and related procedures in hospitals and surgical centers, addressing limitations of autograft (donor site morbidity), allograft (disease transmission risk), and existing rhBMP-2 products (supraphysiological dosing and inflammatory side effects). LDGraft received FDA Breakthrough Device designation in May 2023, and the RESTORE clinical study commenced US enrollment in November 2024. The company is a spin-out from the University of Nottingham (founded on the regenerative medicine research of Professor Kevin Shakesheff) and has raised over £27 million in cumulative funding from Mercia Ventures, BGF, MEIF, and Innovate UK.

Locate Bio currently generates no product revenue; its commercial model is built around future direct sales to healthcare institutions via clinical field sales representatives, with complementary out-licensing potential for its TAOS and IntraStem platforms. Revenue mechanics will activate post-regulatory approval, with the US market (over 700,000 spinal fusions annually) as the primary near-term opportunity, supported by a wholly-owned US subsidiary, Locate Bio Inc.

Locate Bio firmographics

Firmographics
Name
Locate Bio
Legal name
Locate Bio Ltd
Website
https://locatebio.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Locate Bio is a UK clinical-stage orthobiologics company developing polymer-encapsulated rhBMP-2 bone graft substitutes and instructive tissue scaffolds for spine and orthopedic surgeons, with LDGraft in US clinical trials for spinal fusion.
Ownership category
akta.pro rank

Locate Bio industry classification

Industry
Product category
Orthobiologics — Bone Graft Substitutes
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Orthobiologics products
  • Bone graft substitutes
  • Spinal fusion devices
  • Tissue engineering scaffolds
  • Controlled drug release

Where Locate Bio is headquartered

Location

Headquarters

HQ city
Nottingham
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Locate Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Product Sales (Post-Approval): Revenue from sales of LDGraft, CertOss, and other orthobiologics products to hospitals and surgeons upon regulatory approval. Currently pre-revenue as products are in clinical development stage.
  2. Licensing and Partnerships: Potential out-licensing or partnering opportunities for proprietary technologies including TAOS platform and IntraStem gene therapy technology to pharmaceutical and medical device companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Locate Bio product offering

Product offering

Core offering

Locate Bio develops and manufactures orthobiologics products — bone graft substitutes and tissue scaffolds — for use by spine and orthopedic surgeons in spinal fusion, bone infection, and cartilage repair procedures. Its portfolio combines Programmed Drug Release technology (sustained, biomimetic rhBMP-2 delivery) with Instructive Tissue Scaffold technology (100% synthetic calcium phosphate scaffolds), producing products such as LDGraft, CertOss, OsteoMime, CognitOss, and Chondro3.

Product overview

Locate Bio is a diversified orthobiologics company developing multiple product families using two core technology platforms: Programmed Drug Release and Instructive Tissue Scaffolds. The portfolio includes LDGraft (controlled-release rhBMP-2 for spinal fusion), CertOss (100% synthetic bone graft scaffold), OsteoMime (second-generation rhBMP-2 product for revision surgeries), CognitOss (antibiotic-delivering bone graft for osteomyelitis), and Chondro3 (biomimetic cartilage repair graft). The products address unmet musculoskeletal needs in spinal fusion, bone infection treatment, and cartilage repair.

Differentiator

Problem solved

Functional benefit

Brands

  • LDGraft: rhBMP-2 bone graft substitute product for spinal fusion with FDA breakthrough device designation
  • CertOss
  • OsteoMime
  • CognitOss
  • Chondro3

Products and services

  • LDGraft™ A next-generation bone graft substitute for spinal fusion featuring 100% pre-encapsulated recombinant human bone morphogenetic protein-2 (rhBMP-2) with controlled and extended release over 4-6 weeks. Uses Dose Shielding technology to shield rhBMP-2 during the early inflammatory phase and enables a biomimetic release profile aligned with the 7-14 day natural peak of BMP-2 expression in human bone healing. Investigational use only; holds FDA Breakthrough Device designation for ALIF.
  • CertOss™ A 100% synthetic bone graft substitute using Instructive Tissue Scaffold technology. Developed through R&D evaluating geometries to deliver novel bone graft properties based on discoveries that new bone forms preferentially on concave surfaces of ceramic grafts and that submicron surface topography differences result in enhanced bone mineralization.
  • OsteoMime™ A second rhBMP-2 product in development using Programmed Drug Release technology, currently in stealth mode, designed to address unmet needs in revision spinal surgeries.
  • CognitOss Controlled and responsive release of antibiotics from a resorbable bone graft for the treatment of osteomyelitis (bone infections). Combines local delivery of therapeutically appropriate levels of antibiotics from a smart material responsive to the presence of infection while promoting bone regeneration. Received FDA Breakthrough Device designation.
  • Chondro3

Quantifiable outcome

  • All three rhBMP-2 doses tested were equivalent to iliac crest bone graft in terms of fusion at 6 months in sheep model
  • +2 more outcomes

Companies that use Locate Bio

Customer profile

Segments2 records

Ideal customer profiles1 record

Locate Bio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Locate Bio partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor and major.

  • European Orthopaedics Company (unnamed)minorOEM/ Whitelabel/ Licensing Partner · 3 September 2021TAOS technology partnered with a major European orthopaedics company for osteomyelitis treatment application.
  • Royal College of Surgeons in Ireland (RCSI)majorStrategic or Co-development Partner · 1 September 2020Locate Bio acquired multiple late-stage complementary orthobiologics assets from RCSI University of Medicine and Health Sciences, accelerating route to market and broadening orthobiologics pipeline with products including CertOss, CognitOss, and Chondro3.
  • University of NottinghammajorStrategic or Co-development Partner · 16 October 2018Locate Bio is a spin-out from the University of Nottingham based on the research of Professor Kevin Shakesheff, a world-leading expert in regenerative medicine. The company was initially a contract research organization before pivoting to orthobiologics product development.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Locate Bio competitors and assessment

Company assessment

Direct peers

  • SeaSpine: SeaSpine (now part of Globus Medical) is a spine-focused orthobiologics company offering bone graft substitutes and spinal fusion products. Its portfolio overlaps directly with Locate Bio's spinal fusion and bone graft ambitions, and Keith Valentine served as its CEO, illustrating the direct comparability.
  • Bioventus: Bioventus is an orthobiologics-focused company offering bone graft substitutes and regenerative medicine products for spine and orthopedic applications. Its portfolio overlaps with Locate Bio's CertOss and CognitOss franchises, making it a comparable pure-play orthobiologics peer.
  • Orthofix Medical: Orthofix is a spine and orthopedics company with a meaningful orthobiologics segment including bone graft substitutes. Its BGM (Biologics) product line directly competes with Locate Bio's CertOss and LDGraft in the spinal fusion call point.
  • Xtant Medical: Xtant Medical is a clinical-stage and commercial orthobiologics company developing bone graft substitutes and regenerative products for spinal and orthopedic surgery. Its product portfolio and pipeline stage are highly comparable to Locate Bio's diversified orthobiologics approach.
  • MTF Biologics: MTF Biologics is a leading tissue bank and orthobiologics provider offering allograft bone graft substitutes for spinal fusion and orthopedic applications. Its allograft-based offerings compete directly with Locate Bio's synthetic CertOss and LDGraft products.

Broad incumbents

  • Baxter International: Baxter acquired ApaTech (where Locate Bio's CEO previously served) for $330M, validating the strategic value of differentiated orthobiologics assets. As a major medical device incumbent with a bone graft substitute franchise, Baxter represents both a competitor and a potential strategic acquirer profile.
  • NuVasive: NuVasive (now part of Globus Medical) is a major spine surgery company with a substantial orthobiologics portfolio. Its spinal fusion franchise and biologics offerings compete in the same surgeon call point as Locate Bio, and Keith Valentine previously served as President and COO.
  • Medtronic (INFUSE Bone Graft): Medtronic markets INFUSE, the established rhBMP-2 bone graft substitute that LDGraft is designed to displace or compete against in spinal fusion. As the dominant incumbent in rhBMP-2 delivery with decades of clinical data and entrenched surgeon relationships, it is the most direct competitive benchmark for Locate Bio's lead program.

Emerging players

  • Prosidyan: Prosidyan (acquired by Globus Medical) developed synthetic bone graft substitutes with biologic activity for spine and orthopedic surgery. Its focus on synthetic, growth-factor-enhanced grafts is directly comparable to Locate Bio's CertOss and LDGraft strategy.
  • Bone Biologics: Bone Biologics is a clinical-stage orthobiologics company developing bone graft substitutes for spinal fusion using rhBMP-2. It is a direct competitor to Locate Bio's LDGraft in the same indication, technology class, and clinical development stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Locate Bio social profiles

Digital presence

Locate Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Locate Bio leadership team

Management profile

Number of profiles

Profiles12 records

Locate Bio subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Locate Bio funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Locate Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Locate Bio

What does Locate Bio do?

Locate Bio develops and manufactures orthobiologics products — bone graft substitutes and tissue scaffolds — for use by spine and orthopedic surgeons in spinal fusion, bone infection, and cartilage repair procedures. Its portfolio combines Programmed Drug Release technology (sustained, biomimetic rhBMP-2 delivery) with Instructive Tissue Scaffold technology (100% synthetic calcium phosphate scaffolds), producing products such as LDGraft, CertOss, OsteoMime, CognitOss, and Chondro3.

Is Locate Bio a public or private company?

Locate Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Locate Bio founded?

Locate Bio was founded in 2018. It employs 11 to 50 people.

Where is Locate Bio based?

Locate Bio is headquartered in Nottingham, United Kingdom, in the Europe region.

How does Locate Bio make money?

Two revenue lines are on record. Product Sales (Post-Approval) is the primary driver. The others are licensing and Partnerships.

Who are Locate Bio's main competitors?

Direct peers on record are SeaSpine, Bioventus, Orthofix Medical, Xtant Medical and MTF Biologics. Broad incumbents are Baxter International, NuVasive and Medtronic (INFUSE Bone Graft). Emerging players are Prosidyan and Bone Biologics.

Does Locate Bio have an API?

No public API is recorded for Locate Bio.

What industry is Locate Bio in?

Locate Bio's product category is Orthobiologics — Bone Graft Substitutes. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials). Its NAICS code is 325414 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Locate Bio: Orthobiologics Company Raises £9.2 MillionLocate Bio completed an oversubscribed £9.2 million funding round from investors Mercia Ventures and BGF to finance the RESTORE clinical trial for its bone graft substitute, LDGraft. The proceeds will support the study of this FDA breakthrough device, which utilizes a proprietary protein encapsulation method to deliver rhBMP-2 for spinal fusion.FinSMEsLocate Bio Raises £9.2M in FundingLocate Bio, a UK orthobiologics firm, raised £9.2M in funding led by Mercia Ventures and BGF. The company will use the funds to advance its clinical study of LDGraft, a bone graft substitute for spinal fusion that received FDA breakthrough device designation in 2023.BusinessCloudLocate Bio raises £9.2m to develop bone graft substituteLocate Bio raised £9.2 million to fund a clinical study of LDGraft, a bone graft substitute for spinal fusion. The funding comes from new and existing investors, Mercia Ventures and BGF, and the company says it marks a milestone in its mission to relieve orthopaedic suffering.BusinessCloudLocate Bio raises £9.2m to develop bone graft substituteLocate Bio has secured £9.2 million in funding from Mercia Ventures and BGF to finance the RESTORE clinical study for its bone graft substitute, LDGraft. The company aims to use these funds to advance its proprietary protein encapsulation technology toward regulatory approval and global market entry.Business Wire BlogLocate Bio Raises £9.2 Million to Progress LDGraft Clinical Study for Anterior Lumbar Interbody FusionLocate Bio has completed an oversubscribed £9.2 million funding round led by new and existing investors Mercia Ventures and BGF to advance its clinical study for LDGraft, a bone graft substitute for anterior lumbar interbody fusion. The proceeds will fund the RESTORE trial, which aims to evaluate the efficacy of this proprietary rhBMP-2 delivery system in treating spinal fusion patients. This development marks a significant milestone following the product's receipt of FDA breakthrough device designation in 2023.LocatebioLocate Bio Raises £9.2m for LDGraft ALIF Study – Locate BioLocate Bio has completed an oversubscribed £9.2 million funding round to support its clinical study of LDGraft, a bone graft substitute for spinal fusion, on April 29, 2024. This funding is aimed at progressing the RESTORE clinical trial, which is a significant milestone for the company's mission in advancing orthobiologics. The successful funding reflects strong investor confidence in the potential of LDGraft and its applications for patients suffering from severe back pain.FinSMEsLocate Bio Raises £10M in FundingLocate Bio, a regenerative medicine company based in Nottingham, raised £10 million in equity funding co-led by Mercia Asset Management and BGF. The company plans to use the capital to advance its proprietary pipeline of orthobiologics products through key clinical and regulatory milestones over the next two years.LocatebioLocate Bio Closes £10 million Funding Round – Locate BioLocate Bio has closed an oversubscribed £10 million equity funding round co-led by Mercia Asset Management and new investor BGF. The capital will be used to advance the company's pipeline of regenerative orthobiologics, including products like LDGraft and CognitOss, towards clinical and regulatory milestones.Silicon CanalsUK’s Locate Bio raises €11.64M to develop its pipeline of regenerative orthobiologics productsLocate Bio raised an oversubscribed £10M (approx €11.64M) equity round co-led by Mercia Asset Management and BGF, bringing total capital to over £18M. The funds will accelerate development of its orthobiologics pipeline, including LDGraft and other products, with clinical and regulatory milestones expected over the next two years.Business Wire BlogLocate Bio Closes £10 Million Funding RoundLocate Bio raised an oversubscribed £10 million equity round co-led by Mercia Asset Management and BGF. The funds will advance its regenerative orthobiologics pipeline, including LDGraft for degenerative disc disease, bringing total funds raised to over £18 million.